Vertex Pharmaceuticals Incorporated (VRTX) Free Cash Flow Yield: 3.31%
Is Vertex Pharmaceuticals Incorporated’s free cash flow yield high or low?
Vertex Pharmaceuticals Incorporated's free cash flow yield of 3.31% is 14% below its 5-year average of 3.85%, near the low end of its 5-year range (2.50%–6.21%).
The free cash flow yield for Vertex Pharmaceuticals Incorporated (VRTX) is 3.31% as of Wednesday, June 10, 2026. It is above its 12-month average by 8.43% (3.05%).
VRTX Free Cash Flow Yield Chart
VRTX Average Free Cash Flow Yield Chart
VRTX Current vs Average Free Cash Flow Yield Chart
VRTX Free Cash Flow Yield Metrics
FREE CASH FLOW YIELD
3.31%
FREE CASH FLOW YIELD AVG TTM
3.05%
FREE CASH FLOW YIELD AVG 3Y
3.42%
FREE CASH FLOW YIELD AVG 5Y
3.85%
FREE CASH FLOW YIELD AVG 10Y
3.12%
FREE CASH FLOW YIELD AVG 15Y
3.05%
FREE CASH FLOW YIELD AVG 20Y
3.05%
CURRENT VS TTM AVG
+8.43%
CURRENT VS 3Y AVG
-3.31%
CURRENT VS 5Y AVG
-13.99%
CURRENT VS 10Y AVG
+6.26%
CURRENT VS 15Y AVG
+8.57%
CURRENT VS 20Y AVG
+8.57%
VRTX Competitors' Free Cash Flow Yield
| NAME | MARKET CAP | FREE CASH FLOW YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Vertex Pharmaceuticals Incorporated (VRTX) | — | 3.31% | 3.05% | 3.42% | 3.85% |
| Bristol-Myers Squibb Company (BMY) | $114.14B | 10.43% | 13.31% | 12.26% | 10.96% |
| Medtronic plc (MDT) | $103.04B | 5.25% | 4.52% | 4.48% | 4.31% |
| CVS Health Corporation (CVS) | $125.16B | 5.89% | 6.53% | 9.25% | 10.66% |
| Danaher Corporation (DHR) | $130.25B | 4.03% | 3.49% | 3.47% | 3.67% |
| Elevance Health Inc. (ELV) | $87.43B | 7.27% | 5.89% | 5.04% | 6.07% |
| Cigna Corporation (CI) | $78.25B | 9.80% | 8.62% | 9.50% | 9.22% |
| Pfizer Inc. (PFE) | $146.36B | 6.45% | 7.35% | 5.93% | 7.34% |
| Intuitive Surgical, Inc. (ISRG) | $146.44B | 1.90% | 1.28% | 0.87% | 1.09% |
| Gilead Sciences, Inc. (GILD) | $151.21B | 6.70% | 6.08% | 7.45% | 8.69% |
Yield Comparison
FCF Yield
3.31%
Earnings Yield
3.86%
Dividend Yield
N/A
Formula: FCF Yield = (Free Cash Flow / Market Cap) × 100
How FCF Yield is used:
- Shows free cash flow after capital expenditures relative to market cap
- Can be compared with earnings yield and dividend yield
- Can be compared with the company's historical range
- Can be compared with peers that report positive free cash flow
FCF vs earnings: Differences between FCF yield and earnings yield can reflect capital expenditures, working capital changes, and other non-cash accounting items.
Vertex Pharmaceuticals Incorporated Free Cash Flow Yield Formula & Definition
FCF Yield measures free cash flow relative to market capitalization. It compares cash generation after capital expenditures with the equity value of the company.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Vertex Pharmaceuticals Incorporated Free Cash Flow Yield FAQ
- What is the free cash flow yield for Vertex Pharmaceuticals Incorporated (VRTX)?
- The free cash flow yield for VRTX stock is 3.31%.
- Is Vertex Pharmaceuticals Incorporated's free cash flow yield high or low?
- Vertex Pharmaceuticals Incorporated's free cash flow yield of 3.31% is 14% below its 5-year average of 3.85%, near the low end of its 5-year range (2.50%–6.21%).
- What is the TTM average free cash flow yield for Vertex Pharmaceuticals Incorporated (VRTX)?
- The TTM average free cash flow yield for VRTX stock is 3.05%.
- What is the 3Y average free cash flow yield for Vertex Pharmaceuticals Incorporated (VRTX)?
- The 3Y average free cash flow yield for VRTX stock is 3.42%.
- What is the 5Y average free cash flow yield for Vertex Pharmaceuticals Incorporated (VRTX)?
- The 5Y average free cash flow yield for VRTX stock is 3.85%.
- What is the 10Y average free cash flow yield for Vertex Pharmaceuticals Incorporated (VRTX)?
- The 10Y average free cash flow yield for VRTX stock is 3.12%.
- What is the 15Y average free cash flow yield for Vertex Pharmaceuticals Incorporated (VRTX)?
- The 15Y average free cash flow yield for VRTX stock is 3.05%.
- What is the 20Y average free cash flow yield for Vertex Pharmaceuticals Incorporated (VRTX)?
- The 20Y average free cash flow yield for VRTX stock is 3.05%.
Vertex Pharmaceuticals Incorporated Free Cash Flow Yield History
| DATE | FREE CASH FLOW YIELD |
|---|---|
| 2026-06-10 | 3.31% |
| 2026-06-09 | 3.25% |
| 2026-06-08 | 3.27% |
| 2026-06-05 | 3.24% |
| 2026-06-04 | 3.28% |
| 2026-06-03 | 3.38% |
| 2026-06-02 | 3.41% |
| 2026-06-01 | 3.30% |
| 2026-05-29 | 3.23% |
| 2026-05-28 | 3.23% |
| 2026-05-27 | 3.31% |
| 2026-05-26 | 3.32% |
| 2026-05-22 | 3.33% |
| 2026-05-21 | 3.34% |
| 2026-05-20 | 3.36% |
| 2026-05-19 | 3.33% |
| 2026-05-18 | 3.32% |
| 2026-05-15 | 3.31% |
| 2026-05-14 | 3.21% |
| 2026-05-13 | 3.19% |
| 2026-05-12 | 3.23% |
| 2026-05-11 | 3.33% |
| 2026-05-08 | 3.37% |
| 2026-05-07 | 3.41% |
| 2026-05-06 | 3.39% |
| 2026-05-05 | 3.41% |
| 2026-05-04 | 2.90% |
| 2026-05-01 | 2.94% |
| 2026-04-30 | 2.92% |
| 2026-04-29 | 2.95% |
| 2026-04-28 | 2.90% |
| 2026-04-27 | 2.93% |
| 2026-04-24 | 2.90% |
| 2026-04-23 | 2.87% |
| 2026-04-22 | 2.85% |
| 2026-04-21 | 2.86% |
| 2026-04-20 | 2.84% |
| 2026-04-17 | 2.83% |
| 2026-04-16 | 2.86% |
| 2026-04-15 | 2.82% |
| 2026-04-14 | 2.81% |
| 2026-04-13 | 2.83% |
| 2026-04-10 | 2.86% |
| 2026-04-09 | 2.79% |
| 2026-04-08 | 2.81% |
| 2026-04-07 | 2.89% |
| 2026-04-06 | 2.87% |
| 2026-04-02 | 2.84% |
| 2026-04-01 | 2.79% |
| 2026-03-31 | 2.79% |
| 2026-03-30 | 2.81% |
| 2026-03-27 | 2.88% |
| 2026-03-26 | 2.75% |
| 2026-03-25 | 2.74% |
| 2026-03-24 | 2.78% |
| 2026-03-23 | 2.76% |
| 2026-03-20 | 2.75% |
| 2026-03-19 | 2.72% |
| 2026-03-18 | 2.76% |
| 2026-03-17 | 2.70% |
| 2026-03-16 | 2.68% |
| 2026-03-13 | 2.66% |
| 2026-03-12 | 2.61% |
| 2026-03-11 | 2.53% |
| 2026-03-10 | 2.50% |
| 2026-03-09 | 2.71% |
| 2026-03-06 | 2.73% |
| 2026-03-05 | 2.71% |
| 2026-03-04 | 2.61% |
| 2026-03-03 | 2.63% |
| 2026-03-02 | 2.57% |
| 2026-02-27 | 2.51% |
| 2026-02-26 | 2.60% |
| 2026-02-25 | 2.58% |
| 2026-02-24 | 2.56% |
| 2026-02-23 | 2.59% |
| 2026-02-20 | 2.62% |
| 2026-02-19 | 2.66% |
| 2026-02-18 | 2.65% |
| 2026-02-17 | 2.61% |
| 2026-02-13 | 2.54% |
| 2026-02-12 | 2.79% |
| 2026-02-11 | 2.81% |
| 2026-02-10 | 2.79% |
| 2026-02-09 | 2.75% |
| 2026-02-06 | 2.71% |
| 2026-02-05 | 2.82% |
| 2026-02-04 | 2.75% |
| 2026-02-03 | 2.78% |
| 2026-02-02 | 2.74% |
| 2026-01-30 | 2.76% |
| 2026-01-29 | 2.72% |
| 2026-01-28 | 2.71% |
| 2026-01-27 | 2.73% |
| 2026-01-26 | 2.72% |
| 2026-01-23 | 2.77% |
| 2026-01-22 | 2.77% |
| 2026-01-21 | 2.81% |
| 2026-01-20 | 2.93% |
| 2026-01-16 | 2.94% |
| 2026-01-15 | 2.95% |
| 2026-01-14 | 2.88% |
| 2026-01-13 | 2.85% |
| 2026-01-12 | 2.81% |
| 2026-01-09 | 2.79% |
| 2026-01-08 | 2.76% |
| 2026-01-07 | 2.68% |
| 2026-01-06 | 2.77% |
| 2026-01-05 | 2.89% |
| 2026-01-02 | 2.87% |
| 2025-12-31 | 2.86% |
| 2025-12-30 | 2.86% |
| 2025-12-29 | 2.82% |
| 2025-12-26 | 2.80% |
| 2025-12-24 | 2.80% |
| 2025-12-23 | 2.82% |
| 2025-12-22 | 2.81% |
| 2025-12-19 | 2.84% |
| 2025-12-18 | 2.90% |
| 2025-12-17 | 2.88% |
| 2025-12-16 | 2.85% |
| 2025-12-15 | 2.84% |
| 2025-12-12 | 2.87% |
| 2025-12-11 | 2.91% |
| 2025-12-10 | 2.91% |
| 2025-12-09 | 2.96% |
| 2025-12-08 | 2.93% |
| 2025-12-05 | 2.84% |
| 2025-12-04 | 2.83% |
| 2025-12-03 | 2.80% |
| 2025-12-02 | 2.99% |
| 2025-12-01 | 3.04% |
| 2025-11-28 | 2.99% |
| 2025-11-26 | 3.00% |
| 2025-11-25 | 3.01% |
| 2025-11-24 | 3.06% |
| 2025-11-21 | 3.04% |
| 2025-11-20 | 3.07% |
| 2025-11-19 | 3.08% |
| 2025-11-18 | 2.97% |
| 2025-11-17 | 2.99% |
| 2025-11-14 | 2.96% |
| 2025-11-13 | 2.98% |
| 2025-11-12 | 2.98% |
| 2025-11-11 | 3.02% |
| 2025-11-10 | 3.08% |
| 2025-11-07 | 3.16% |
| 2025-11-06 | 3.11% |
| 2025-11-05 | 3.11% |
| 2025-11-04 | 3.07% |
| 2025-11-03 | 3.17% |
| 2025-10-31 | 3.18% |
| 2025-10-30 | 3.22% |
| 2025-10-29 | 3.24% |
| 2025-10-28 | 3.20% |
| 2025-10-27 | 3.22% |
| 2025-10-24 | 3.21% |
| 2025-10-23 | 3.20% |
| 2025-10-22 | 3.17% |
| 2025-10-21 | 3.17% |
| 2025-10-20 | 3.23% |
| 2025-10-17 | 3.24% |
| 2025-10-16 | 3.31% |
| 2025-10-15 | 3.31% |
| 2025-10-14 | 3.28% |
| 2025-10-13 | 3.32% |
| 2025-10-10 | 3.31% |
| 2025-10-09 | 3.26% |
| 2025-10-08 | 3.21% |
| 2025-10-07 | 3.29% |
| 2025-10-06 | 3.35% |
| 2025-10-03 | 3.35% |
| 2025-10-02 | 3.31% |
| 2025-10-01 | 3.34% |
| 2025-09-30 | 3.45% |
| 2025-09-29 | 3.42% |
| 2025-09-26 | 3.50% |
| 2025-09-25 | 3.54% |
| 2025-09-24 | 3.59% |
| 2025-09-23 | 3.56% |
| 2025-09-22 | 3.53% |
| 2025-09-19 | 3.53% |
| 2025-09-18 | 3.49% |
| 2025-09-17 | 3.49% |
| 2025-09-16 | 3.45% |
| 2025-09-15 | 3.44% |
| 2025-09-12 | 3.43% |
| 2025-09-11 | 3.40% |
| 2025-09-10 | 3.48% |
| 2025-09-09 | 3.41% |
| 2025-09-08 | 3.42% |
| 2025-09-05 | 3.41% |
| 2025-09-04 | 3.41% |
| 2025-09-03 | 3.41% |
| 2025-09-02 | 3.37% |
| 2025-08-29 | 3.46% |
| 2025-08-28 | 3.45% |
| 2025-08-27 | 3.47% |
| 2025-08-26 | 3.49% |
| 2025-08-25 | 3.48% |
| 2025-08-22 | 3.42% |
| 2025-08-21 | 3.40% |
| 2025-08-20 | 3.43% |
| 2025-08-19 | 3.46% |
| 2025-08-18 | 3.47% |
| 2025-08-15 | 3.44% |
| 2025-08-14 | 3.46% |
| 2025-08-13 | 3.41% |
| 2025-08-12 | 3.49% |
| 2025-08-11 | 3.61% |
| 2025-08-08 | 3.69% |
| 2025-08-07 | 3.60% |
| 2025-08-06 | 3.51% |
| 2025-08-05 | 3.60% |
| 2024-08-01 | 2.68% |
| 2024-07-31 | 2.73% |
| 2024-07-30 | 2.70% |
| 2024-07-29 | 2.72% |
| 2024-07-26 | 2.74% |
| 2024-07-25 | 2.75% |
| 2024-07-24 | 2.76% |
| 2024-07-23 | 2.76% |
| 2024-07-22 | 2.73% |
| 2024-07-19 | 2.76% |
| 2024-07-18 | 2.78% |
| 2024-07-17 | 2.77% |
| 2024-07-16 | 2.77% |
| 2024-07-15 | 2.76% |
| 2024-07-12 | 2.77% |
| 2024-07-11 | 2.75% |
| 2024-07-10 | 2.76% |
| 2024-07-09 | 2.79% |
| 2024-07-08 | 2.81% |
| 2024-07-05 | 2.85% |
| 2024-07-03 | 2.88% |
| 2024-07-02 | 2.86% |
| 2024-07-01 | 2.88% |
| 2024-06-28 | 2.89% |
| 2024-06-27 | 2.87% |
| 2024-06-26 | 2.86% |
| 2024-06-25 | 2.86% |
| 2024-06-24 | 2.85% |
| 2024-06-21 | 2.89% |
| 2024-06-20 | 2.87% |
| 2024-06-18 | 2.90% |
| 2024-06-17 | 2.86% |
| 2024-06-14 | 2.82% |
| 2024-06-13 | 2.83% |
| 2024-06-12 | 2.85% |
| 2024-06-11 | 2.81% |
| 2024-06-10 | 2.80% |
| 2024-06-07 | 2.81% |
| 2024-06-06 | 2.79% |
| 2024-06-05 | 2.81% |
| 2024-06-04 | 2.85% |
| 2024-06-03 | 2.88% |
| 2024-05-31 | 2.98% |
| 2024-05-30 | 3.06% |
| 2024-05-29 | 3.07% |
| 2024-05-28 | 3.03% |
Showing the most recent 260 of 2,595 data points. The chart above shows the full history.
About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated is a leading biotechnology firm primarily focused on the discovery, advancement, and marketing of innovative treatments, particularly for cystic fibrosis (CF). The company offers a range of approved medications for CF patients, including SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO, which target specific mutations within the cystic fibrosis transmembrane conductance regulator gene. Additionally, they provide TRIKAFTA for individuals with CF aged six years and older who possess at least one F508del mutation. Beyond its established CF therapies, Vertex maintains a robust and diverse clinical pipeline. This includes VX-864, currently in Phase 2 for alpha-1 antitrypsin (AAT) deficiency; VX-147, also in Phase 2, addressing APOL1-mediated focal segmental glomerulosclerosis (FSGS) and other serious kidney conditions; VX-880, a potential treatment for Type 1 Diabetes undergoing Phase 1/2 trials; VX-548, a NaV1.8 inhibitor in Phase 2 for various forms of acute, neuropathic, and musculoskeletal pain; and CTX001, which is in Phase 3 development for severe sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT). The company distributes its pharmaceutical products through specialty pharmacies and distributors across the United States, while international sales are facilitated via a network of specialty distributors, retail chains, hospitals, and clinics. Vertex also engages in numerous strategic collaborations with partners such as Affinia Therapeutics, Arbor Biotechnologies, CRISPR Therapeutics, Kymera Therapeutics, Mammoth Biosciences, Moderna, Obsidian Therapeutics, Skyhawk Therapeutics, Ribometrix, Genomics plc, Merck KGaA, and X-Chem. Established in 1989, Vertex Pharmaceuticals is headquartered in Boston, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Reshma Kewalramani